Major Thalassemia. Beta thalassaemia
Conditions
Interventions
Intervention 1: Desferrixamine alone 50-60 mg/kg/day. Intervention 2: Combination therapy of deferiprone 50-75 mg/kg/day and desferrioxamine 30-35 mg/kg/day.
Treatment - Drugs
Desferrixamine alone 50-60 mg/kg/day
Combination therapy of deferiprone 50-75 mg/kg/day and desferrioxamine 30-35 mg/kg/day
Sponsors
Mazndaran University of Medical Science
Eligibility
Sex/Gender
All
Age
5 Years to 30 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1- Confirmed major thalassemia by Hemoglubin elctrophoresis 2- Age ranged 5-30 years 3- Serum ferritin level more than 3000 ng/ml 4- Written consent from patients or parents Exclusion criteria: 1- Disagreement of patients or parents for begining of treatment 2- Deferiprone sensitivity 3- Desferrioxamine sensitivity 3-
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum ferritin. Timepoint: 6 months. Method of measurement: Immuno Radiaometric Assay.;Left ventricle ejection fraction. Timepoint: 6 months. Method of measurement: Echocardiography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hemoglobin. Timepoint: 6 months. Method of measurement: Electronic counter.;AST. Timepoint: 6 months. Method of measurement: PARS AZMUN Kit.;ALT. Timepoint: 6 months. Method of measurement: PARS AZMUN Kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Karami
Mazndaran University of Medical Science
Outcome results
None listed